Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease Dear Sir, In their letter Mühlhauser et al. [1] suspect that the reduced mortality rate achieved in intensively insulin-treated Type II diabetic patients after myocardial infarction compared with a conventionally treated Type II diabetic control group in the DIGAMI study [2] may be due to avoiding sulphonylurea drugs in the study group rather than to acute or chronic metabolic improvement induced by insulin-glucose infusion immediately after myocardial infarction followed by subcutaneous insulin treatment. To strengthen their hypothesis of sulphonylurea drugs being ªcardiovascular killersª they refer to data from the University Group Diabetes Program (UGDP) reporting increased cardiovascular mortality in tolbutamide treated patients. As a possible explanation for a potentially lethal effect by sulphonylureas in coronary artery disease an aggravation of hypoxic myocardial damage subsequent to coronary occlusion is offered [3] . This phenomenon is to be mediated via a sulphenylurea dependent blockade of cardiovascular ATP-sensitive potassium (K ATP ) channels [4] .
Yet, before drawing this conclusion some important points should be kept in mind: first, the results of the UGDP study have not been simply ªcompletely overlookedª [1] but have been extensively discussed and criticised for at least a decade [5] . Thus, their clinical relevance is still questionable. Interestingly, a recent paper even reports reduced cardiovascular mortality following long-term tolbutamide treatment in a small cohort of subjects with impaired glucose tolerance compared with untreated subjects [6] . While these results may not be extrapolated to Type II diabetic patients, the United Kingdom Prospective Diabetes Study (UKPDS) which was started in 1977 and reaches its projected end 1997 has, up to now, not reported any overmortality in the sulphonylurea treated group [7] . Thus, without anticipating the definitive final results, no overtly detrimental impact of sulphonylureas on total and cardiovascular mortality is to be expected. In the context of recent findings [3] , this is remarkable as in the UKPDS glibenclamide was used mainly, which in vitro interferes strongly with vascular K ATP channels [4] . Moreover, being aware of the unique properties of individual sulphonylurea compounds including their different affinity to pancreatic and extrapancreatic K ATP channels [4] as well as some antioxidative effects [8] caution is required as to class effects of sulphonylureas on cardiovascular mortality.
There are also some details in the design of the DIGAMI study which need to be considered. This includes, in particular, correction of hyperglycaemia by continuous intravenous insulin-glucose infusion after diagnosis of myocardial infarction [2] . This procedure induces rapid changes in the tissue substrate-flows of both carbohydrates and fatty acids, and thereby ameliorates metabolism in surviving myocardial tissue. Such rapid correction of hyperglycaemia and its negative sequelae as done in the DIGAMI study appears to be favourable to minimise postischaemic cardiac damage and to improve primarily short-and, consequently also, long-term prognosis of diabetic patients [2] . Furthermore, it was shown recently that perfusion of isolated rat hearts with diabetic ( = hyperglycaemic) blood prior to induced ischaemia amplified the myocardial reperfusion injury when compared with the effect of perfusion with non-diabetic ( = euglycaemic) blood, possibly by impairing haemorheological properties and generating oxygen free radicals [9] . The encounter of these disturbances with antioxidative action possibly explains improved postischaemic recovery of cardiac functions in diabetic rats following gliclazide treatment [8] .
From the above it appears that the interpretation of the DI-GAMI results as evidence of a general cardiotoxicity of sulphonylureas is mere speculation as, in particular, the published DIGAMI data neither enable a definitive allocation of survivors and non-survivors to sulphonylurea ªpre-treatmentº before infarction nor to ªfollow-upº treatment with sulphonylureas after infarction. Even, if most of the patients in the conventionally treated group had taken sulphonylurea drugs, no general conclusion could be drawn since, as pointed out above, individual sulphonylurea drugs differ substantially in their effects and side-effects. It is therefore that Leibowitz and Cerasi put a question mark at the end of the title of their review ªSul-phonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?º [10] .
However, although I am convinced that drug therapy should be put onto the test stand critically, any indiscriminate condemnation of a drug class as widely prescribed as sulphonylureas without more ªevidence based medicineº than hypothetical speculation is unjustified and may rattle doctors and frighten their patients. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease Dear Sir, We are grateful for the possibility to expand further on our above referenced hypothesis [1] in response to the letter by Dr. Fasching. Even though the relevance of the results of the UGDP ± as devastating for sulphonylureas and biguanides as they were ± may have been debatable [2] , there has never been a study to rule out any cardiotoxic effect of sulphonylurea therapy. Recent findings in animals and humans have provided a pathophysiological plausibility for our hypothesis, as sulphonylureas appear to aggravate the hypoxaemic damage to the myocardium in the case of coronary occlusion or artery disease [1, 3, 4, 5] . In fact, such a pathophysiological scenario fits well with the observation that the alleged cardiotoxic effect of sulphonylureas appears to exert itself in an increased lethality of myocardial (re-) infarctions or cardiac death rates, rather than by increasing cardiac events or the incidence of cardiovascular morbidity [1, 7] . In this situation, appropriate studies directed at efficacy and safety of sulphonylurea drugs have been demanded recently [5, 6, 8] .
The UKPDS is certainly not going to be helpful in this context, as patients with clinically relevant coronary artery disease have been excluded during the recruitment process: the entire cohort included only 3 % patients with a history of angina pectoris (excluding those with present angina), 2 % with a history of myocardial infarction (prior to 1 year before recruitment) and patients with heart failure were excluded [9] . Furthermore, the study does not have the statistical power to rule out clinically relevant differences concerning cardiovascular morbidity and mortality between the four treatment arms represented under Intensive Therapy [9, 10] .
Finally, we agree with Dr. Fasching that sulphonylureas must not be judged as a drug class; rather more every sulphonylurea drug needs to be studied individually for its effectivity and safety vis-à-vis the relevant endpoints for Type II diabetes mellitus, i. e. cardiovascular morbidity and mortality ± rather than being limited to surrogate markers [11] . The fact that any such positive evidence has never been demonstrated for this (and any other) oral antidiabetic drug is most disturbing and, indeed, should alarm the ªdoctors and frighten their patientsº.
In our opinion, the ± albeit incomplete ± evidence implementing a cardiotoxic effect of sulphonylurea drugs has become substantial enough to shift the burden of proof on to those who are still using sulphonylurea drugs in Type II diabetic patients with coronary heart disease to document that this is actually safe.
Yours sincerely, M. Berger, I. Mühlhauser, PT Sawicki
